Psychedelic-Drug Developers Bring Hallucinogens To The World Of Therapeutics

On May 26 2021 MindMed (NASDAQ: MNMD), a leading psychedelic medicine biotech company, announced the publication of the first pharmacogenetic data on LSD to help personalize dosing.

MindMed is a clinical-stage, neuro-pharmaceutical biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to improve health, promote wellness and alleviate suffering, addressing addiction and mental illness.

MindMed is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC.

The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic inspired medicines and therapies.

The firm also develops a non-hallucinogenic version of the psychedelic ibogaine.

The news that has MNMD stock higher today is a Type C Meeting Responses from the FDA. This allows the company to finalize Project Lucy with Generalized Anxiety Disorder as its initial indication.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ. For more information please visit

More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. TheraPure Health Essentials would like to help bring awareness.

Invest today! Type 'MNMD' in the search bar here.